The precursor for nerve growth factor (proNGF) is not a serum or biopsy-rinse biomarker for thyroid cancer diagnosis

Abstract Background: Nerves and neurotrophic growth factors are emerging promoters of cancer growth. The precursor for Nerve Growth Factor (proNGF) is overexpressed in thyroid cancer, but its potential role as a clinical biomarker has not been reported. Here we have examined the value of proNGF as a serum and biopsy-rinse biomarker for thyroid cancer diagnosis. Methods: Patients presenting for thyroid surgery or biopsy were enrolled in separate cohorts examining serum (n=204, including 46 cases of thyroid cancer) and biopsy-rinse specimens (n=188, including 26 cases of thyroid cancer). ProNGF levels in clinical samples were analysed by ELISA. Multivariate statistical analyses testing for potential confounders were used to compare proNGF levels with clinicopathological parameters. Results: ProNGF was not detected in the majority of serum samples 176/204 (86%) and the detection of proNGF was not associated with thyroid cancer diagnosis. In the few cases where proNGF was detected in the serum, thyroidectomy did not affect proNGF concentration, demonstrating that the thyroid was not the source of serum proNGF. Intringuingly, an association between hyperthyroidism and serum proNGF was observed (OR 3.3, 95%CI 1.6-8.7 p=0.02). In biopsy-rinse, proNGF was detected in 73/188 (39%) cases, with no association between proNGF and thyroid cancer. However, a significant positive association between follicular lesions and biopsy-rinse proNGF was found (OR 3.3, 95% CI 1.2-8.7, p=0.02). Conclusions: ProNGF levels in serum and biopsy-rinse are not increased in thyroid cancer and therefore proNGF is not a clinical biomarker for this condition.